18 Fubini, B., Ghiazza, M., and Fenoglio, I. (2010). Physico‐chemical features of engineered nanoparticles relevant to their toxicity. Nanotoxicology 4: 347–363. https://doi.org/10.3109/17435390.2010.509519.
19 Gabizon, A., Catane, R., Uziely, B. et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene‐glycol coated liposomes. Cancer Research 54 (4): 987–992.
20 Gabizon, A., de Rosales, R., and La‐Beck, N. (2020). Translational considerations in nanomedicine: the oncology perspective. Advanced Drug Delivery Reviews 158: 140–157. https://doi.org/10.1016/j.addr.2020.05.012.
21 Gatoo, M., Naseem, S., Arfat, M. et al. (2014). Physicochemical properties of nanomaterials: implication in associated toxic manifestations. BioMed Research International 2014: 1–8. https://doi.org/10.1155/2014/498420.
22 Gaur, N., Sharma, N., Dahiya, A. et al. (2020). Toxicity and Regulatory Concerns for Nanoformulations in Medicine. Beverly, MA: Scrivener Publishing LLC.
23 George, S., Ho, S., Wong, E. et al. (2015). The multi‐facets of sustainable nanotechnology ‐ lessons from a nanosafety symposium. Nanotoxicology 9 (3): 404–406. https://doi.org/10.3109/17435390.2015.1027315.
24 Germain, M., Caputo, F., Metcalfe, S. et al. (2020). Delivering the power of nanomedicine to patients today. Journal of Controlled Release 326: 164–171. https://doi.org/10.1016/j.jconrel.2020.07.007.
25 Greish, K., Mathur, A., Bakhiet, M., and Taurin, S. (2018). Nanomedicine: is it lost in translation? Therapeutic Delivery 9 (4): 1–18. https://doi.org/10.4155/tde‐2017‐0118.
26 Guadagnini, R., Kenzaoui, B.H., Walker, L. et al. (2015). Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology 9 (Suppl 1): 13–24. https://doi.org/10.3109/17435390.2013.829590.
27 Hasan, A., Morshed, M., Memic, A. et al. (2018). Nanoparticles in tissue engineering: applications, challenges and prospects. Internal Journal of Nanomedicine 13: 5637–5655. https://doi.org/10.2147/IJN.S153758.
28 Havel, H., Finch, G., Strode, P. et al. (2016). Nanomedicines: from bench to bedside and beyond. The AAPS Journal 18 (6): 1373–1378. https://doi.org/10.1208/s12248‐016‐9961‐7.
29 Heinrich, M., Martina, B., and Prakash, J. (2020). Nanomedicine strategies to target coronavirus. Nano Today 35: 1–21. https://doi.org/10.1016/j.nantod.2020.100961.
30 Jeevanandam, J., Barhoum, A., Chan, Y. et al. (2018). Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein Journal of Nanotechnology 9: 1050–1074. https://doi.org/10.3762/bjnano.9.98.
31 Juillerat‐Jeanneret, L., Dusinska, M., Fjellsbo, L. et al. (2015). Biological impact assessment of nanomaterial used in nanomedicine: introduction to the NanoTEST project. Nanotoxicology 9 (Suppl 1): 5–12. https://doi.org/10.3109/17435390.2013.826743.
32 Khan, F. (2020). Nanomaterials: Types, Classifications, and Sources. Singapore: Springer Nature.
33 Khan, S., Hasan, A., Attar, F. et al. (2020). Gold nanoparticle‐based platforms for diagnosis and treatment of myocardial infarction. ACS Biomaterials Science & Engineering 6 (12): 6460–6477. https://doi.org/10.1021/acsbiomaterials.0c00955.
34 Klaine, S., Alvarez, P., Batley, G. et al. (2008). Nanomaterials in the environment: behavior, fate, bioavailability, and effects. Environmental Toxicology and Chemistry 27 (9): 1825–1851.
35 Koziorowski, J., Stanciu, A., Gomez‐Vallejo, V., and Llop, J. (2017). Radiolabeled nanoparticles for cancer diagnosis and therapy. Anti‐Cancer Agents in Medicinal Chemistry 17 (3): 333–354. https://doi.org/10.2174/1871520616666160219162902.
36 Krukemeyer, M., Krenn, V., and Huebner, F. (2015). History and possible uses of nanomedicine based on nanoparticles and nanotechnological progress. Journal of Nanomedicine & Nanotechnology 06 (06): 1–7. https://doi.org/10.4172/2157‐7439.1000336.
37 Kubinova, S. and Sykova, E. (2010). Nanotechnologies in regenerative medicine. Minimally Invasive Therapy 19 (3): 144–156. https://doi.org/10.3109/13645706.2010.481398.
38 Lombardo, D., Kiselev, M., and Caccamo, M. (2019). Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. Journal of Nanomaterials 2019: 1–26. https://doi.org/10.1155/2019/3702518.
39 Lopalco, A. and Denora, N. (2018). Nanoformulations for Drug Delivery: Safety, Toxicity, and Efficacy, 2018/06/24e, vol. 1800. New York: Humana Press.
40 Makvandi, P., Ghomi, M., Padil, V. et al. (2020). Biofabricated nanostructures and their composites in regenerative medicine. ACS Applied Nano Materials 3 (7): 6210–6238. https://doi.org/10.1021/acsanm.0c1164.
41 Martins, J., das Neves, J., de la Fuente, M. et al. (2020). The solid progress of nanomedicine. Drug Delivery and Translational Research 10 (3): 726–729. https://doi.org/10.1007/s13346‐020‐00743‐2.
42 McDonald, T., Siccardi, M., Moss, D. et al. (2015). The application of nanotechnology to drug delivery in medicine. In: Nanoengineering (ed. P. Dolez), 173–223. Amsterdam: Elsevier.
43 McGoron, A. (2020). Perspectives on the future of nanomedicine to impact patients: an analysis of US federal funding and interventional clinical trials. Bioconjugate Chemistry 31 (3): 436–447. https://doi.org/10.1021/acs.bioconjchem.9b00818.
44 Mukherjee, B., Dey, N., Maji, R. et al. (2014). Current status and future scope for nanomaterials in drug delivery. In: Application of Nanotechnology in Drug Delivery (ed. A. Sezer). London: IntechOpen.
45 Oberdorster, G. (2010). Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. Journal of Internal Medicine 267 (1): 89–105. https://doi.org/10.1111/j.1365‐2796.2009.02187.x.
46 Oberdörster, G., Oberdörster, E., and Oberdörster, J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 113 (7): 823–839. https://doi.org/10.1289/ehp.7339.
47 Oberdörster, G., Stone, V., and Donaldson, K. (2009). Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1 (1): 2–25. https://doi.org/10.1080/17435390701314761.
48 Osman, N.M., Sexton,